ibodutant
Sign in to saveAlso known as MEN 15596
Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. , it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06.
~2 min read
Encyclopedic overview
3 sectionsContents
- See also
- References
- Further reading
{{Drugbox | Verifiedfields = changed | verifiedrevid = 444434892 | IUPAC_name = Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide | image = Ibodutant_structure.svg | image_class = skin-invert-image | width = 150px
| tradename = | pregnancy_category = | legal_status = | routes_of_administration = Oral
Excerpted from Wikipedia’s “ibodutant” article, available under the CC BY-SA 4.0 licence.